A judge has now ruled a CVS partner will have to pay just under $289 million in a judgement. Nearly a decade ago a ...

This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research ...

With many PBMs receiving scrutiny, smaller startups that bill themselves as more transparent are seeing interest from employers in the state and nationally.

In this final video of a three-part video series, Joshua Fredell, Pharm.D., senior vice president at CVS Caremark and a ...

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

Few People Know About These Hidden Features Handyman tips! so many amazing different inventions and master tips. tools , home improvement , diy projects , useful things , cool tools , diy tools , inve ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...